A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Safety and Efficacy of YH22162 in Subjects With Essential Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
Phase of Trial: Phase III
Latest Information Update: 17 Feb 2017
At a glance
- Drugs Amlodipine/chlortalidone/telmisartan (Primary) ; Amlodipine/telmisartan
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Yuhan
- 14 Feb 2017 Status changed from active, no longer recruiting to completed.
- 06 Dec 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2016.
- 16 Oct 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.